Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
about
Does HAART efficacy translate to effectiveness? Evidence for a trial effectEfficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsAntiretroviral regimens for patients with HIV who fail first-line antiretroviral therapySystematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesDarunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIVAbacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensViral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic reviewEfavirenz and the CNS: what we already know and questions that need to be answeredProtease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitroACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentMinor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureA strategy to model nonmonotonic dose-response curve and estimate IC50Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012Ongoing trials in HIV protease inhibitors.Tuberculosis and HIV: a partnership against the most vulnerable.CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.A synergistic small-molecule combination directly eradicates diverse prion strain structuresQuantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.Use of observational data in evaluating treatments: antiretroviral therapy and HIV.Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.Modelling imperfect adherence to HIV induction therapyThe Surprising Role of Amyloid Fibrils in HIV InfectionEfavirenz in the therapy of HIV infection.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataModulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
P2860
Q21135313-E64DBED8-0A2A-4A78-A8CD-18A22CAD3518Q21144607-A998DF30-3960-4C80-B7C3-27D70E854526Q24243499-A4A3EF5A-29D0-41D3-B9CB-DCD511D91B5FQ24514773-7B91D03F-589B-45F6-8E4B-14890C322008Q24597052-7CEB1A3A-88CA-4F01-B6B9-4BE8075879CEQ24681002-1ED40DA5-C2A6-4E53-9DCF-5071449F3552Q24799351-4EC8F1BC-2143-4F9D-95D9-9745010D2FC5Q26823588-16BF4D32-DE0F-4D52-B783-7D383904E5F8Q28085028-E7C8ABBD-CB4C-4247-B938-D4144C5877DDQ28190771-B9D41834-028D-4BDC-8490-299C51C52E8FQ28344457-9401969D-D71B-4F9F-A330-B89BA1EEB2E4Q28362567-21AF913A-7725-454A-A6F5-60D3C871177BQ28362780-4210A93D-8F2B-4FC7-A601-1948E96B4AE3Q28471623-32284C0B-C65A-433A-9B0F-021DE509663AQ28478779-E5BC5914-B8A7-4C50-BA42-C1BEC7A38F58Q28535044-7833A685-502C-4D5C-A783-AEB62F249D6FQ28539652-07D35565-D01A-45FE-AC93-0B2F00B02FEAQ30327423-BE075F0D-4E92-4C40-B95A-DDAA12BBDA5EQ30336184-6006B4A1-0102-4737-B002-D3BEB6EBB542Q30438405-680568A1-1FCC-42E5-AEB2-0667BFD4EFD9Q30834094-88701DB4-BF23-4A2F-AC7D-B28D78FF1172Q30885765-772F4131-213D-4E32-9752-315D0A122418Q30892194-367904A8-27AA-479F-8F10-A27F3565CDFDQ30969932-4E52F96C-89B6-4530-A751-57AA7678B820Q31159582-463F3CEF-0429-40D8-B81E-AEC9F3E9AC1DQ33258171-01A5760E-E3EA-45CD-94AC-C3DD9D61724AQ33436334-CB799FD0-12EF-4D43-8FE6-D22B2BF891D8Q33523201-F080CB64-A5EB-4FF8-894A-D24D2D77F636Q33570363-80FFA7C8-1E5E-4AEA-9D53-CB841226274FQ33607011-0BF4CC06-1B78-4BE9-ACFC-FEFFE95E7FD6Q33649563-FEA833D9-2FA0-44CE-B787-A3D7802AA6C4Q33814896-87735E45-D3BB-4C41-90CB-61D369EA626AQ33821729-9AE6A27E-A04B-4B12-B758-985D04E40E8BQ33843148-5F2BC471-5DC2-4F70-A76A-F4685D6009EFQ33851627-A81FCBA1-D022-43AA-9F6D-3365235BA793Q33872810-C6E03659-220A-4D13-A4DC-6A8FE992C8EAQ33873983-4C5B95C4-07C6-48FA-93F5-E07E506EE613Q33891656-5DBF9E9B-5A51-47A8-BBA4-6CB639E2B624Q33945359-1F8CA362-5816-4732-A761-F775ED29E35BQ33980528-67B7B009-6C76-423A-8E96-10B01E7D2AB9
P2860
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@en
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@nl
type
label
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@en
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@nl
prefLabel
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@en
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@nl
P2093
P1476
Efavirenz plus zidovudine and ...... ion in adults. Study 006 Team.
@en
P2093
D F Labriola
D J Manion
J Morales-Ramirez
J Stanford
K T Tashima
P304
P356
10.1056/NEJM199912163412501
P407
P577
1999-12-01T00:00:00Z